Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy



Status:Recruiting
Conditions:Allergy, Allergy, Food Studies, Neurology
Therapuetic Areas:Neurology, Otolaryngology, Pharmacology / Toxicology
Healthy:No
Age Range:2 - 17
Updated:4/21/2016
Start Date:November 2014

Use our guide to learn which trials are right for you!

A Double-Blind, Placebo-Controlled Randomized Trial to Study the Viaskin Milk Efficacy and Safety for Treating IgE-Mediated Cow's Milk Allergy in Children

The objectives of this study are to evaluate the safety and efficacy of Viaskin Milk after
12 months of epicutaneous immunotherapy (EPIT) treatment, for desensitizing IgE-mediated
cow's milk allergic children.


Inclusion Criteria:

- Signed Informed Consent Form (ICF) by parent(s)/guardian(s) of subjects and informed
assent form (IAF) for subjects ≥7 years, or as per local or country specific
guidelines or regulations.

- Male or female subjects 2 to 17 years old at Visit 1.

- Documented medical history or physician-confirmed diagnosis of IgE-mediated CMA with
systemic symptoms related to ingestion of milk or dairy products.

- Subjects currently following a strict cow's milk-free diet, with no consumption of
dairy or baked milk products.

- Cow's milk-specific IgE level at screening ≥10 kU/L

- Positive Skin Prick Test (SPT) to cow's milk with a largest wheal diameter ≥6 mm.

- Positive DBPCFC at screening with an eliciting dose ≤300 mg cow's milk proteins
(approximately ≤9.4 mL of cow's milk).

- Negative urine pregnancy test for female subjects of childbearing potential. Female
subjects of childbearing potential must agree and commit to use effective medical
methods of contraception for the entire duration of their participation in the study.
Sexual abstinence will be accepted as an effective method of contraception for girls
below 15 years of age.

- Ability to perform spirometry procedures in accordance with the American Thoracic
Society guidelines (2005) for subjects ≥6 years old. Ability to perform peak
expiratory flow (PEF) measurements for subjects ≥5 years old. Subjects <8 years of
age who have documented inability to adequately perform spirometry can perform only
the PEF evaluation. Subjects <5 years of age may be enrolled if they had no clinical
features of moderate or severe persistent asthma severity (as defined by the 2007
National Heart, Lung, and Blood Institute [NHLBI] Guidelines) within 1 year before
Visit 1.

- Subjects and/or parents/guardians willing to comply with all study requirements
during participation in the study.

Exclusion Criteria:

- History of severe anaphylaxis to cow's milk resulting in hypotension, hypoxia or
neurological compromise (collapse, loss of consciousness or incontinence) or
requiring mechanical ventilation.

- Pregnancy or lactation.

- Spirometry forced expiratory volume in 1 second (FEV1) <80% of the predicted value at
Visit 1 for subjects ≥6 years and able to perform the spirometry, or PEF <80% of
predicted value at Visit 1 for subjects performing only the PEF measurements.

- Any clinical features of moderate or severe persistent asthma severity (as defined by
the 2007 NHLBI guidelines) and high daily doses of inhaled corticosteroids.

- Known allergy to the Viaskin patch materials or excipients, or to any of the
components of the food challenge formulas other than the cow's milk proteins.

- Allergy or known history of reaction to Tegaderm® medical dressing with no
possibility to use an alternative adhesive dressing authorized by the sponsor in
replacement.

- Subjects having objective symptoms to the placebo formula leading to stopping the
challenge during the screening DBPCFC.

- Severe reaction during the screening DBPCFC defined as need for intubation, and/or
hypotension persisting after epinephrine administration, and/or the need for >2 doses
of epinephrine.

- Symptomatic allergy to pollens with symptoms during the pollen season that might
interfere with the symptoms observed during the DBPCFC, if the DBPCFC is performed
during the pollen season. Screening of such subjects should be made out of the pollen
season.

- Inability to discontinue short-acting antihistamines for 3 days or long-acting
antihistamines for 5 to 7 days (depending on the half-life) before the DBPCFC.

- Use of systemic long-acting corticosteroids within 12 weeks before Visit 1 and/or use
of systemic short-acting corticosteroids within 4 weeks before Visit 1 or use of
long-acting or short-acting corticosteroids during screening (unless used to treat
symptoms triggered by the DBPCFC).

- Subjects with asthma conditions meeting 1 or several criteria below:

- Uncontrolled persistent asthma (as defined by the 2007 NHLBI guidelines) or
subject being treated with a combination therapy of medium or high daily dose of
inhaled corticosteroid with a long acting inhaled β2-agonist. Intermittent
asthmatic subjects who require intermittent use of inhaled corticosteroids for
rescue are permitted.

- At least 2 systemic corticosteroid courses for asthma within 1 year before Visit
1 or 1 oral corticosteroid course for asthma within 3 months before Visit 1, or
during screening (unless used to treat symptoms triggered by the DBPCFC).

- Prior intubation/mechanical ventilation due to asthma within 2 years before
Visit 1, or during screening.

- Upper respiratory infection or gastroenteritis within 7 days of DBPCFC (DBPCFC must
then be rescheduled at least 7 days after resolution of these conditions).

- Any history of milk immunotherapy (eg, oral immunotherapy, sublingual immunotherapy
or specific oral tolerance induction).

- Prior history of any other food allergen immunotherapy (eg, oral immunotherapy,
sublingual immunotherapy or specific oral tolerance induction) within 5 years before
Visit 1.

- Subjects currently under aeroallergen immunotherapy and unwilling or unable to
discontinue at the time of Visit 1. Aeroallergen Immunotherapy must be discontinued
at the time of Visit 1.

- Use of any anti-IgE drug (eg, omalizumab), any immunomodulatory therapy, or any
biological agent therapy (eg, anti-tumor necrosis factor drugs) within 1 year before
Visit 1, or during screening.

- Generalized dermatologic diseases (eg, severe atopic dermatitis, uncontrolled
generalized eczema, icthyosis vulgaris) with no intact zones to apply the Viaskin
patch, or urticarial and mast cells disorders such as chronic idiopathic urticaria.

- Subject and/or subject's parents/guardians with obvious excessive anxiety and
unlikely to cope with the conditions of a food challenge.

- Past or current disease, including but not limited to active eosinophilic
gastrointestinal disorders, autoimmune disorders, immunodeficiency, malignancy,
uncontrolled disease (hypertension, diabetes, psychiatric disorder, cardiac disease),
or other disorders (eg, liver, gastrointestinal, kidney, cardiovascular, pulmonary
disease or blood disorder) which in the opinion of the Investigator or the sponsor
may affect the subject's participation in the study or place the subject at increased
risk.

- Subjects and/or parents/guardians unable to use the epinephrine auto-injector
properly in spite of being adequately trained.

- Contraindicated condition for the use of epinephrine.

- Use of any investigational drug or device, or participation in another interventional
clinical study within 3 months before Visit 1.

- Subjects receiving beta-blockers or Angiotensin converting-enzyme (ACE) inhibitors.

- Subjects unable to follow the protocol requirements.
We found this trial at
13
sites
291 Campus Dr
Stanford, California 94305
(650) 725-3900
Principal Investigator: Kari Nadeau, MD
Phone: 650-724-0293
Stanford University School of Medicine Vast in both its physical scale and its impact on...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Wayne Shreffler, MD
Phone: 617-643-5833
?
mi
from
Boston, MA
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Principal Investigator: Anna Nowak-Wegrzyn, MD
Phone: 212-241-2000
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Terri Brown-Whitehorn, MD
Phone: 267-426-8657
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: David M. Fleischer, MD
Phone: 720-777-2575
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1800 Orleans St.
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Robert Wood, MD
Phone: 410-502-1711
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Principal Investigator: Melanie Makhija, MD
Phone: 312-227-6474
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1935 Medical District Dr
Dallas, Texas 75235
(214) 456-7000
Principal Investigator: Drew Bird, MD
Phone: 214-456-5142
Children's Medical Center of Dallas Children's Medical Center is private, not-for-profit, and is the fifth-largest...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: Stacie M. Jones, MD
Phone: 501-364-1060
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Mississauga, Ontario
Principal Investigator: Amarjit Cheema, MD
Phone: 0019055661200
?
mi
from
Mississauga,
Click here to add this to my saved trials
3414 Fifth Avenue
Pittsburgh, Pennsylvania 15213
Principal Investigator: Todd Green, MD
Phone: 412-692-7885
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
San Diego, California 92123
Principal Investigator: Stephanie Leonard, MD
Phone: 858-966-8153
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Seattle, Washington 98105
Principal Investigator: Stephen Tilles, MD
Phone: 206-525-5520
?
mi
from
Seattle, WA
Click here to add this to my saved trials